Cover Page - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 |
Mar. 14, 2023 |
Jun. 30, 2022 |
|
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Document Period End Date | Dec. 31, 2022 | ||
| Document Fiscal Year Focus | 2022 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | IKT | ||
| Entity Registrant Name | INHIBIKASE THERAPEUTICS, INC. | ||
| Entity Central Index Key | 0001750149 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Emerging Growth Company | true | ||
| Entity Small Business | true | ||
| Entity Ex Transition Period | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity Shell Company | false | ||
| Entity Common Stock, Shares Outstanding | 28,977,238 | ||
| Entity Public Float | $ 18.7 | ||
| Entity Tax Identification Number | 26-3407249 | ||
| Entity Interactive Data Current | Yes | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Security Exchange Name | NASDAQ | ||
| Documents Incorporated by Reference | None | ||
| Entity Address, Address Line One | 3350 Riverwood Parkway SE | ||
| Entity Address, Address Line Two | Suite 1900 | ||
| Entity Address, City or Town | Atlanta | ||
| Entity Address, State or Province | GA | ||
| Entity Address, Postal Zip Code | 30339 | ||
| City Area Code | 678 | ||
| Local Phone Number | 392-3419 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Title of 12(b) Security | Common Stock, $0.001 par value | ||
| Securities Act File Number | 001-39676 | ||
| Auditor Name | CohnReznick LLP | ||
| Auditor Firm ID | 596 | ||
| Auditor Location | Holmdel, New Jersey | ||
| Amendment Description | This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of Inhibikase Therapeutics, Inc. for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 31, 2023 (the “Original Filing”). The Consent of Independent Registered Public Accounting Firm (the “Auditor Consent”) was inadvertently omitted in the Original Filing. This Amendment is being filed solely to file the Auditor Consent. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the date of the Original Filing or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant’s other filings with the Securities and Exchange Commission. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment. |